Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) at the 2025 PNS Meeting
May 09, 2025 17:00 ET | Source: Annexon Biosciences First Oral Presentation…
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
April 03, 2025 18:18 ET | Source: Annexon Biosciences Oral Plenary Presentation…